Table 1. Clinical and laboratory characteristics of 889 patients with myelodysplastic syndrome stratified by the absolute lymphocyte count and absolute monocyte count.
| Variables | All patients, n=889 | Patients with subnormal absolute lymphocyte count, n=261 (Group A) | Patients with absolute lymphocyte count with in the normal range, n=598 (Group B) | P-value (A vs B) | Patients with absolute monocyte count <0.3 × 109/l, n=539 (Group C) | Patients with absolute monocyte count ⩾0.3 × 109/l, n=350 (Group D) | P-value (C vs D) |
|---|---|---|---|---|---|---|---|
| Age (years), median (range) | 72 (18–98) | 74 (25–94) | 71 (23–98) | 0.06 | 71 (18–98) | 74 (24–95) | <0.0001 |
| Gender (males), n (%) | 616 (69) | 192 (73) | 409 (68) | 0.1 | 366 (68) | 250 (71) | 0.3 |
| Hemoglobin g/dl, median (range) | 9.6 (5.4–15.7) | 9.3 (5.8–14.6) | 9.8 (5.4–15.7) | 0.002 | 9.4 (5.4–15.7) | 9.9 (6.2–15.7) | 0.005 |
| Hemoglobin<10 g/dl, n (%) | 506 (57) | 169 (65) | 318 (53) | 0.002 | 327 (60) | 179 (51) | 0.005 |
| Transfusion needs, n (%) | 295 (33) | 111 (42) | 178 (30) | 0.0003 | 194 (36) | 101 (29) | 0.03 |
| Leukocyte count × 109/l, median (range) | 3.4 (0.4–35) | 2.4 (0.4–19.2) | 3.5 (0.9–35) | <0.0001 | 2.7 (0.4–19.2) | 4.8 (0.7–35) | <0.0001 |
| Bone marrow blast %, median (range) | 3 (0–19) | 0 (0–18) | 3 (0–19) | 0.7 | 4 (0–19) | 2 (0–19) | <0.0001 |
| Circulating blasts %, median (range) | 0 (0–18) | 0 (0–18) | 0 (0–18) | 0.2 | 0 (0–18) | 0 (0–18) | 0.03 |
| Platelet count × 109/l, median (range) | 106 (2–1804) | 79 (2–800) | 116 (7–1804) | <0.0001 | 91 (2–993) | 134 (4–1804) | <0.0001 |
| Platelet count<100 × 109/l, n (%) | 424 (48) | 151 (57) | 259 (43) | <0.0001 | 289 (54) | 135 (38) | <0.0001 |
| Absolute neutrophil count<0.8 × 109/l, median (range) | 237 (27) | 82 (31) | 151 (25) | 0.06 | 194 (36) | 43 (12) | <0.0001 |
| Abnormal cytogenetics, n (%) | 438 (49) | 131 (50) | 295 (49) | 0.8 | 281 (52) | 157 (45) | 0.03 |
| IPSS-R, n (%) | |||||||
| Very high | 97 (11) | 32 (12) | 62 (11) | 0.1 | 75 (14) | 22 (6) | <0.0001 |
| High | 141 (16) | 47 (18) | 90 (15) | 101 (18) | 40 (12) | ||
| Intermediate | 186 (21) | 60 (23) | 120 (20) | 138 (26) | 48 (14) | ||
| Low | 319 (36) | 92 (35) | 217 (36) | 167 (31) | 152 (43) | ||
| Very low | 146 (16) | 30 (12) | 109 (18) | 58 (11) | 88 (25) | ||
| Total | 889 | 261 | 598 | 539 | 350 | ||
| IPSS-R cytogenetic risk group, n (%) | |||||||
| Very good | 44 (5) | 12 (5) | 32 (5) | 0.9 | 24 (4) | 20 (6) | 0.03 |
| Good | 566 (63) | 165 (63) | 381 (64) | 328 (61) | 238 (68) | ||
| Intermediate | 160 (18) | 48 (18) | 106 (17) | 103 (19) | 57 (16) | ||
| Poor | 34 (4) | 11 (4) | 22 (4) | 20 (4) | 14 (4) | ||
| Very poor | 85 (10) | 25 (10) | 57 (10) | 64 (12) | 21 (6) | ||
| Total | 889 | 261 | 598 | 539 | 350 | ||
| Leukemic transformation, n (%) | 116 (13) | 29 (11) | 85 (14) | 0.2 | 78 (14) | 38 (10) | 0.1 |
| Deaths, n (%) | 712 (80) | 218 (83) | 465 (78) | 435 (81) | 277 (79) | ||
Abbreviation: IPSS-R, Revised International Prognostic Scoring System (hemoglobin, g/dl; absolute neutrophil count, × 109/l; platelets, × 109/l; bone marrow blast, cytogenetic category).
Reference normal range: absolute lymphocyte count, (0.9–2.9) × 109/l, absolute monocyte count (0.3–0.9) × 109/l, (Mayo Clinic Laboratory).
Clinical and laboratory characteristics for patients with ALC above normal (n=30) have not been shown in the table. The values in bold represent the P-values found to be significant on analysis.